Program
paxalisib
Also written as “SVG103”, “Paxalisib (GDC-0084)” and “[14C]-Paxalisib Capsule”.
Its studies are mostly in Glioblastoma · Tuberous Sclerosis, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kazia Therapeutics | 20 open or running | phase 2since Mar 20, 2018 | Mar 20, 2018 | none ahead |
| Hoffmann-La Roche | 10 open or running | phase 1since Mar 5, 2012 | Mar 5, 2012 | none ahead |
| Sovargen | 11 open or running | phase 2since Dec 11, 2025 | Dec 11, 2025 | Feb 2027phase 2 · NCT07287202 |
Also a collaborator on its studies: quotient-sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 5, 2012First study: phase 1 study in GlioblastomaNew to Hoffmann-La RocheHoffmann-La Roche · NCT01547546 · 29 enrolled · United States, Spain
- Mar 20, 2018Kazia Therapeutics's first study: phase 2 study in GlioblastomaNew to Kazia TherapeuticsKazia Therapeutics · NCT03522298 · 30 enrolled · United States
- Aug 4, 2021Phase 1 study in HealthyKazia Therapeutics · NCT05012670 · 6 enrolled · United Kingdom
- Dec 11, 2025Sovargen's first study: phase 2 study in Focal Cortical DysplasiaNew to SovargenSovargen · NCT07287202 · 12 planned · Australia
Ahead
- Feb 2027Primary completion: phase 2 study in Focal Cortical DysplasiaSovargen · NCT07287202
TargetBeta
“PI3-kinase class I inhibitor”ChEMBL 37, by rule
Other programs on the same 8 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| gedatolisibrule | Pfizer | phase 3 | 9 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07287202Focal Cortical Dysplasia · Australia | 2 | Recruiting | Sovargen | Feb 2027 | 12 |
| NCT05012670Healthy · United Kingdom | 1 | Completed | Kazia Therapeutics | Mar 30, 2023 | 6 |
| NCT03522298Glioblastoma · United States | 2 | Completed | Kazia Therapeutics | Mar 30, 2023 | 30 |
| NCT01547546Glioblastoma · United States, Spain | 1 | Completed | Hoffmann-La Roche | Jan 2015 | 29 |
How it is read
Names in the registry
- “SVG103”, 1 entry
- “Paxalisib (GDC-0084)”, 1 entry
- “[14C]-Paxalisib Capsule”, 1 entry
- “GDC-0084”, 1 entry
Conditions, from the studies’ own filings
- Glioblastoma, 2 studies
- Tuberous Sclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.